MIR-200 family induces mesenchymal-to-epithelial transition (MET) in ovarian cancer cells
The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET).
1. A method of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering a modified miR-429, wherein the modified miR-429 comprises a seed sequence, AAUACUG, and further wherein the modified miR-429 comprises one or more nucleotide substitutions and/or deletions in the nucleotide sequence of SEQ ID NO:5 outside of the seed sequence, to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to cytotoxic therapy.
2. The method of claim 1 , wherein the method further comprises detecting a level of one or more miR-200 family members in ovarian cancer tissue from the subject that is below a reference value prior to administering the modified miR-429 to the subject.
3. The method of claim 1 , wherein the method further comprises detecting cells having a mesenchymal phenotype in ovarian cancer tissue from the subject prior to administering the modified miR-429 to the subject.
4. The method of claim 1 , wherein the method further comprises administering a cytotoxic therapy prior to, concurrently with and/or after administration of the modified miR-429.
5. The method of claim 4 , wherein the cytotoxic therapy comprises a chemotherapy agent.
6. The method of claim 4 , wherein the cytotoxic therapy comprises radiation therapy.
7. The method of claim 1 , wherein the modified miR-429 is transiently delivered by lipofection, a nanoparticle delivery system, or a nanogel delivery system.
8. The method of claim 7 , wherein the method comprises administration of a nanogel delivering the modified miR-429 to the subject, wherein the nanogel comprises a crosslinked polymer particle comprising the active agent non-covalently associated with the nanogel.
9. The method of claim 8 , wherein the crosslinked polymer particle comprises poly(N-isopropylmethacrylamide) and N,N′-methylenebis(acrylamide).
10. The method of claim 8 , wherein the nanogel further comprises a cross-linked polymer shell, wherein the crosslinked polymer shell is disposed substantially around the crosslinked polymer particle.
11. The method of claim 10 , wherein the crosslinked polymer shell comprises poly(N-isopropylmethacrylamide), N,N′-methylenebis(acrylamide), and aminopropylmethacrylamide.
12. The method of claim 1 , wherein a mature modified miR-429 is administered to the subject.
13. The method of claim 1 , wherein a human modified miR-429 is delivered.
14. The method of claim 1 , wherein the subject is a human subject.